FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W604392815> ?p ?o ?g. }

• W604392815 abstract "Abstract BACKGROUND: The inhibitor of the erythrocyte Gardos channel (KCNN-4, IK-1), senicapoc, was developed for treatment of sickle cell disease. Activation of the Gardos channel constitutes a major potassium leak pathway contributing to cellular dehydration. Administration of senicapoc to patients with sickle cell disease was well tolerated and reduced hemolysis through attenuation of sickle red cell dehydration, but failed to reduce the frequency of vaso-occlusive pain crises (Ataga KI et al. Br J Haematol 2011;153:92-104). Red cell volume regulation is critical both to the pathology of sickle cell disease and to the growth of Plasmodium, the parasites that cause malaria, since Plasmodium depends upon ion flow across the host membrane for growth (Glushakova S et al. Curr Biol 2010; 20:1117-1121). We tested the hypothesis that senicapoc-induced blockade of the Gardos channel inhibits intraerythrocytic growth and development of malarial parasites. METHODS: Blood type O+ erythrocytes were infected with P. falciparum strains 3D7, W2mef, and 7G8, and P. knowlesi strains H-1 and YH-1. Parasites were cultured in the presence of senicapoc and in parallel, with drugs with known antimalarial properties (e.g. mefloquine, chloroquine, clotrimazole, and dihydroartemisinin). Parasites were also cultured in the presence of each of eight senicapoc analogs with variable inhibitory potency for the Gardos channel. To define interactions between these drugs, parasites were cultured in fixed-ratio combinations of senicapoc and senicapoc analogs using the fixed-ratio isobologram method. Parasite growth and maturation were determined by microscopy and flow cytometry. The effect of senicapoc in vivo was determined using wild-type C57Bl/6 mice along with IK-1+/+ and IK-1-/- pups on a C57Bl/6 background. Mice were infected with the murine parasite, P. yoelii and treated with senicapoc or vehicle control (methylcellulose 0.5%). RESULTS: We observed that senicapoc blocked the intraerythrocyte growth of P. falciparum 3D7 with an IC50 value of 7 uM and P. knowlesi H1 with an IC50 value of 18 uM. Senicapoc inhibited growth leading to death of intracellular parasites at and beyond the late trophozoite stage, demonstrating minimal effect on ring stage parasites, and an intermediate effect on mature schizonts. Analogs with IC50 values for inhibition of parasite growth similar to senicapoc were potent inhibitors of the Gardos channel. These analogs also shared common elements of the molecular structure. Combined treatment with senicapoc and analogs with potent inhibition of the Gardos channel demonstrated an additive effect on inhibition of parasite growth. Both additive and synergistic interactions were demonstrated when parasites were cultured with senicapoc and analogs without potent inhibition of the Gardos channel. In the murine model, C57Bl/6 mice treated with senicapoc exhibited suppression in parasite growth, confirming the efficacy of senicapoc against Plasmodia in vivo. Parasite growth was suppressed in IK+/+ mice treated with senicapoc, though the effect was not sustained through the period of treatment. Surprisingly, parasite growth was also suppressed in IK-/-mice treated with senicapoc, though the response was delayed. The kinetics of parasite growth differed between mice with and without the Gardos channel. CONCLUSIONS: Senicapoc demonstrates antimalarial activity against P. falciparum and P. knowlesiin vitro and in vivo against P. yoelii in mice. Our in vivo studies suggest a mechanism for inhibition of parasite growth in mice that includes both Gardos-dependent and independent components. The excellent safety profile of senicapoc and its long half-life in humans demonstrated in clinical trials suggest its possible utility in antimalarial development either as a lead compound or in combination with other antimalarials. Disclosures No relevant conflicts of interest to declare." @default.
• W604392815 created "2016-06-24" @default.
• W604392815 creator A5005951342 @default.
• W604392815 creator A5014312110 @default.
• W604392815 creator A5029691139 @default.
• W604392815 creator A5033675456 @default.
• W604392815 creator A5057411925 @default.
• W604392815 creator A5076965086 @default.
• W604392815 creator A5088106803 @default.
• W604392815 date "2014-12-06" @default.
• W604392815 modified "2023-09-26" @default.
• W604392815 title "Senicapoc, a Gardos Channel Inhibitor Developed to Treat Sickle Cell Disease, Exhibits Antimalarial Activity" @default.
• W604392815 doi "https://doi.org/10.1182/blood.v124.21.743.743" @default.
• W604392815 hasPublicationYear "2014" @default.
• W604392815 type Work @default.
• W604392815 sameAs 604392815 @default.
• W604392815 citedByCount "0" @default.
• W604392815 crossrefType "journal-article" @default.
• W604392815 hasAuthorship W604392815A5005951342 @default.
• W604392815 hasAuthorship W604392815A5014312110 @default.
• W604392815 hasAuthorship W604392815A5029691139 @default.
• W604392815 hasAuthorship W604392815A5033675456 @default.
• W604392815 hasAuthorship W604392815A5057411925 @default.
• W604392815 hasAuthorship W604392815A5076965086 @default.
• W604392815 hasAuthorship W604392815A5088106803 @default.
• W604392815 hasConcept C126322002 @default.
• W604392815 hasConcept C153911025 @default.
• W604392815 hasConcept C203014093 @default.
• W604392815 hasConcept C2776120307 @default.
• W604392815 hasConcept C2776557347 @default.
• W604392815 hasConcept C2777208419 @default.
• W604392815 hasConcept C2777425658 @default.
• W604392815 hasConcept C2778048844 @default.
• W604392815 hasConcept C2778371730 @default.
• W604392815 hasConcept C2779902561 @default.
• W604392815 hasConcept C2781160685 @default.
• W604392815 hasConcept C553184892 @default.
• W604392815 hasConcept C71924100 @default.
• W604392815 hasConcept C86803240 @default.
• W604392815 hasConcept C98274493 @default.
• W604392815 hasConceptScore W604392815C126322002 @default.
• W604392815 hasConceptScore W604392815C153911025 @default.
• W604392815 hasConceptScore W604392815C203014093 @default.
• W604392815 hasConceptScore W604392815C2776120307 @default.
• W604392815 hasConceptScore W604392815C2776557347 @default.
• W604392815 hasConceptScore W604392815C2777208419 @default.
• W604392815 hasConceptScore W604392815C2777425658 @default.
• W604392815 hasConceptScore W604392815C2778048844 @default.
• W604392815 hasConceptScore W604392815C2778371730 @default.
• W604392815 hasConceptScore W604392815C2779902561 @default.
• W604392815 hasConceptScore W604392815C2781160685 @default.
• W604392815 hasConceptScore W604392815C553184892 @default.
• W604392815 hasConceptScore W604392815C71924100 @default.
• W604392815 hasConceptScore W604392815C86803240 @default.
• W604392815 hasConceptScore W604392815C98274493 @default.
• W604392815 hasLocation W6043928151 @default.
• W604392815 hasOpenAccess W604392815 @default.
• W604392815 hasPrimaryLocation W6043928151 @default.
• W604392815 hasRelatedWork W1573901295 @default.
• W604392815 hasRelatedWork W1830709691 @default.
• W604392815 hasRelatedWork W1935563522 @default.
• W604392815 hasRelatedWork W1967206933 @default.
• W604392815 hasRelatedWork W2010225387 @default.
• W604392815 hasRelatedWork W2014419556 @default.
• W604392815 hasRelatedWork W2074474663 @default.
• W604392815 hasRelatedWork W2132006467 @default.
• W604392815 hasRelatedWork W2395727861 @default.
• W604392815 hasRelatedWork W2464839201 @default.
• W604392815 hasRelatedWork W2530048705 @default.
• W604392815 hasRelatedWork W3009137732 @default.
• W604392815 isParatext "false" @default.
• W604392815 isRetracted "false" @default.
• W604392815 magId "604392815" @default.
• W604392815 workType "article" @default.